Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Merck
McKesson
Covington
Harvard Business School
Argus Health
QuintilesIMS
Dow
Fish and Richardson

Generated: October 21, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

« Back to Dashboard

Clinical Trials for candesartan cilexetil; hydrochlorothiazide

Trial ID Title Status Sponsor Phase Summary
NCT00383929 Antihypertensive Efficacy and Safety of Candesartan/HCT 32/12.5 and 32/25 mg in Comparison With Candesartan 32 mg Completed AstraZeneca Phase 3 In this study it is intended to compare the blood pressure lowering effect of the combination of candesartan cilexetil (candesartan) 32 mg and hydrochlorothiazide (HCT) 25 mg and the combination of candesartan 32 mg and HCT 12.5 mg to that of candesartan 32 mg alone in patients whose blood pressure is not well controlled on candesartan 32 mg monotherapy. The Primary Objectives are to compare sitting BP lowering effect of candesartan/HCT 32/25 mg and candesartan/HCT 32/12.5 mg with that of candesartan 32 mg, respectively.
NCT00434967 Antihypertensive Efficacy and Safety of Candesartan/HCT 32/25 mg in Comparison With Individual Components and Placebo Completed AstraZeneca Phase 3 The aim is to compare the blood pressure lowering effect of the combination of candesartan cilexetil (candesartan) 32 mg and hydrochlorothiazide (HCT) 25 mg to that of candesartan 32 mg alone, HCT 25 mg alone and placebo in hypertensive adults.
NCT00621153 Candesartan Effect in Second Stage Arterial Hypertension Completed AstraZeneca Phase 4 To compare the changes in mean sitting DBP from baseline after 4 weeks of therapy with either candesartan cilexetil/HCT combination therapy or candesartan cilexetil monotherapy regimen
NCT01012479 Efficacy and Safety of Candesartan Cilexetil Plus Hydrochlorothiazide in Subjects With Severe Hypertension Completed Takeda Phase 4 The purpose of this study is to see if Candesartan, once daily (QD), added with Hydrochlorothiazide may be helpful in treating people with newly diagnosed severe essential hypertension.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for candesartan cilexetil; hydrochlorothiazide

Condition Name

Condition Name for candesartan cilexetil; hydrochlorothiazide
Intervention Trials
Hypertension 5
Stage II Hypertension 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for candesartan cilexetil; hydrochlorothiazide
Intervention Trials
Hypertension 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for candesartan cilexetil; hydrochlorothiazide

Trials by Country

Trials by Country for candesartan cilexetil; hydrochlorothiazide
Location Trials
Ukraine 2
Germany 2
Denmark 1
Malta 1
United Kingdom 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for candesartan cilexetil; hydrochlorothiazide

Clinical Trial Phase

Clinical Trial Phase for candesartan cilexetil; hydrochlorothiazide
Clinical Trial Phase Trials
Phase 4 2
Phase 3 2
Phase 1 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for candesartan cilexetil; hydrochlorothiazide
Clinical Trial Phase Trials
Completed 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for candesartan cilexetil; hydrochlorothiazide

Sponsor Name

Sponsor Name for candesartan cilexetil; hydrochlorothiazide
Sponsor Trials
AstraZeneca 3
Takeda 2
GlaxoSmithKline 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for candesartan cilexetil; hydrochlorothiazide
Sponsor Trials
Industry 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Baxter
Accenture
McKinsey
Mallinckrodt
Fuji
Julphar
Farmers Insurance
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.